 |
|
|
|
|
Advances Made Against Alzheimer's Disease
|
| | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 Detailed measurements showed an increased level of beta amyloid in both blood and cerebrospinal fluid after 12 weeks in those getting the antibody, an indication that the beta amyloid in the brain might be starting to dissolve, the researchers said. New studies of the therapy are planned.
Nixon viewed the results with "tempered optimism." One interesting finding was the response to the therapy was greatest in people who did not have a known genetic marker for Alzheimer's risk, he said. "What is the significance of this? Why do carriers not respond?" Nixon asked. The answer might help explain Alzheimer's disease better, he said.
A third study using a broad spectrum of antibodies was reported by a team at Weill Cornell Medical College in New York City. The treatment, originally developed by Baxter International to treat autoimmune conditions, was given to 24 people with mild to moderate Alzheimer's disease in a set of trials extending as long as 18 months. Statistically significant increases in mental function were seen in those getting the treatment, the researchers said. A large-scale, 18-month follow-up trial will be done.
Text Continues Below
More information
Learn more about Alzheimer's from the Alzheimer's Association.
Page: << Prev | 1 | 2
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 7/31/2008
|
|
SOURCES: Ralph Nixon, M.D., professor, psychiatry and cell biology, New York University; July 30, 2008, presentations, Alzheimer's Association 2008 International Conference on Alzheimer's Disease, Chicago
|
.gif)
